- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07621809
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden (THALASSA)
A Randomized, Double-blind, Placebo-controlled, 2-arm Multicenter Phase III Study to Assess the Efficacy and Safety of Ianalumab in Participants With Sjogren's Disease With High Symptom Burden (THALASSA)
The purpose of this study is to demonstrate the efficacy and safety of ianalumab (VAY736) 300 mg administered subcutaneously (s.c.) monthly for 52 weeks in adult participants with Sjögren's disease who have high symptom burden.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is a double-blind, randomized, placebo-controlled multicenter 2-arm Phase III study, evaluating 300 mg ianalumab s.c. against placebo s.c. in adult participants with Sjögren's disease with high symptom burden.
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: Novartis Pharmaceuticals
- Numéro de téléphone: 1-888-669-6682
- E-mail: novartis.email@novartis.com
Sauvegarde des contacts de l'étude
- Nom: Novartis Pharmaceuticals
- Numéro de téléphone: +41613241111
Lieux d'étude
-
-
-
Erlangen, Allemagne, 91056
- Recrutement
- Novartis Investigative Site
-
-
-
-
Queensland
-
Maroochydore, Queensland, Australie, 4558
- Recrutement
- Novartis Investigative Site
-
-
-
-
São Paulo
-
São Paulo, São Paulo, Brésil, 01232-010
- Recrutement
- Novartis Investigative Site
-
-
-
-
Nova Scotia
-
Sydney, Nova Scotia, Canada, B1P 1P3
- Recrutement
- Novartis Investigative Site
-
-
Quebec
-
Rimouski, Quebec, Canada, G5L 5T1
- Recrutement
- Novartis Investigative Site
-
Sherbrooke, Quebec, Canada, J1E 0N8
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Beijing, Chine, 100730
- Recrutement
- Novartis Investigative Site
-
Beijing, Chine, 100050
- Recrutement
- Novartis Investigative Site
-
Beijing, Chine, 100029
- Recrutement
- Novartis Investigative Site
-
Jiujiang, Chine, 332000
- Recrutement
- Novartis Investigative Site
-
-
Guangdong
-
Shenzhen, Guangdong, Chine, 518020
- Recrutement
- Novartis Investigative Site
-
-
Jiangsu
-
Nanjing, Jiangsu, Chine, 210029
- Recrutement
- Novartis Investigative Site
-
-
Shanxi
-
Taiyuan, Shanxi, Chine, 030000
- Recrutement
- Novartis Investigative Site
-
-
Sichuan
-
Chengdu, Sichuan, Chine, 610041
- Recrutement
- Novartis Investigative Site
-
-
Zhejiang
-
Wenzhou, Zhejiang, Chine, 325000
- Recrutement
- Novartis Investigative Site
-
-
Zhengjiang
-
Ningbo, Zhengjiang, Chine, 315211
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Bogotá, Colombie, 111211
- Recrutement
- Novartis Investigative Site
-
-
Cundinamarca
-
Bogota, Cundinamarca, Colombie, 110221
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Gwangju, Corée du Sud, 61469
- Recrutement
- Novartis Investigative Site
-
Seoul, Corée du Sud, 06591
- Recrutement
- Novartis Investigative Site
-
-
Gyeonggi-do
-
Bundang Gu, Gyeonggi-do, Corée du Sud, 13620
- Recrutement
- Novartis Investigative Site
-
Suwon, Gyeonggi-do, Corée du Sud, 16499
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Madrid, Espagne, 28031
- Recrutement
- Novartis Investigative Site
-
Seville, Espagne, 41009
- Recrutement
- Novartis Investigative Site
-
-
Cantabria
-
Santander, Cantabria, Espagne, 39008
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Dijon, France, 21000
- Recrutement
- Novartis Investigative Site
-
La Roche-sur-Yon, France, 85925
- Recrutement
- Novartis Investigative Site
-
Le Kremlin-Bicêtre, France, 94275
- Recrutement
- Novartis Investigative Site
-
Le Mans, France, 72000
- Recrutement
- Novartis Investigative Site
-
Lille, France, 59037
- Recrutement
- Novartis Investigative Site
-
Montpellier, France, 34295
- Recrutement
- Novartis Investigative Site
-
Paris, France, 75013
- Recrutement
- Novartis Investigative Site
-
Saint-Priest-en-Jarez, France, 42270
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Budapest, Hongrie, 1134
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Belagavi, Inde, 590001
- Recrutement
- Novartis Investigative Site
-
-
Kerala
-
Kochi, Kerala, Inde, 682018
- Recrutement
- Novartis Investigative Site
-
-
Maharashtra
-
Nashik, Maharashtra, Inde, 422101
- Recrutement
- Novartis Investigative Site
-
-
Rajasthan
-
Jaipur, Rajasthan, Inde, 302004
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Graz, L'Autriche, 8036
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Braga, Le Portugal, 4710-243
- Recrutement
- Novartis Investigative Site
-
-
-
-
Provincie Friesland
-
Leeuwarden, Provincie Friesland, Pays-Bas, 8934 AD
- Recrutement
- Novartis Investigative Site
-
-
Provincie Groningen
-
Groningen, Provincie Groningen, Pays-Bas, 9713 GZ
- Recrutement
- Novartis Investigative Site
-
-
South Holland
-
Rotterdam, South Holland, Pays-Bas, 3079 DZ
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Swindon, Royaume-Uni, SN3 6BB
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Košice, Slovaquie, 040 01
- Recrutement
- Novartis Investigative Site
-
Poprad, Slovaquie, 058 01
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Bern, Suisse, 3010
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Hsinchu, Taïwan, 302
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Brno, Tchéquie, 638 00
- Recrutement
- Novartis Investigative Site
-
-
-
-
Arizona
-
Peoria, Arizona, États-Unis, 85381
- Recrutement
- Sun Valley Arthritis Center Ltd
-
Chercheur principal:
- Joy Schechtman
-
Contact:
- Jessica Peters
- Numéro de téléphone: +1 623 825 5591
- E-mail: jessica.peters@sclamanagement.com
-
-
Arkansas
-
Searcy, Arkansas, États-Unis, 72143
- Recrutement
- Unity Health Rheumatology
-
Contact:
- Anita LaMonica
- Numéro de téléphone: +1 501 278 2800
- E-mail: anita.lamonica@unity-health.org
-
Chercheur principal:
- Shailendra K Singh
-
-
California
-
Van Nuys, California, États-Unis, 91405
- Recrutement
- Medvin Clinical Research
-
Chercheur principal:
- Samy Metyas
-
Contact:
- Citlali Garcia
- Numéro de téléphone: +1 626 966 1909
- E-mail: citlali@medvinresearch.com
-
-
Florida
-
Clearwater, Florida, États-Unis, 33765
- Recrutement
- Clinical Res Of W Florida
-
Chercheur principal:
- Rodney Daniel
-
Contact:
- Bridget Huntley
- Numéro de téléphone: +1 727 466 0078
- E-mail: bhuntley@crwf.com
-
Cooper City, Florida, États-Unis, 33024
- Recrutement
- GNP Research
-
Chercheur principal:
- Mark Jaffe
-
Contact:
- Nancy Villalobos
- E-mail: nancy@gnpresearch.com
-
Tampa, Florida, États-Unis, 33606
- Recrutement
- Clinical Research of West Florida Inc
-
Chercheur principal:
- John Carter
-
Contact:
- Sydney K Mullen
- Numéro de téléphone: +1 813 870 1292
- E-mail: smullen@crwf.com
-
-
Illinois
-
Willowbrook, Illinois, États-Unis, 60527
- Recrutement
- Willow Rheumatology Wellness
-
Chercheur principal:
- Angela R Crowley
-
Contact:
- Avni Singh
- Numéro de téléphone: +1 630 794 8649
- E-mail: asingh@willowrheum.com
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02111
- Recrutement
- Tufts Medical Center
-
Chercheur principal:
- Athena Papas
-
Contact:
- Elizabeth Tzavaras
- Numéro de téléphone: +1 504 427 7001
- E-mail: Elizabeth.Tzavaras@tufts.edu
-
-
Michigan
-
Saint Clair Shores, Michigan, États-Unis, 48081
- Recrutement
- Clinical Research Inst of MI
-
Chercheur principal:
- Andrew Sulich
-
Contact:
- Amelia Laurence
- Numéro de téléphone: +1 586 777 7577
- E-mail: alaurence@researchmi.com
-
-
New Jersey
-
Voorhees Township, New Jersey, États-Unis, 08043
- Recrutement
- Arthritis Rheumatology and Bone Disease Associates PA
-
Contact:
- Shannon Chalginow
- Numéro de téléphone: +1856 424 5005
- E-mail: schalginow@arbda.com
-
Chercheur principal:
- Nadishani Dissanayaka
-
-
New York
-
Potsdam, New York, États-Unis, 13676
- Recrutement
- St Lawrence Health System
-
Chercheur principal:
- Eyal Kedar
-
Contact:
- Mckailey Lyndaker
- Numéro de téléphone: +1 315 261 5611
- E-mail: mckailey.lyndaker@rochesterregional.org
-
-
North Carolina
-
Charlotte, North Carolina, États-Unis, 28202
- Recrutement
- On Site Clinical Solutions Llc
-
Chercheur principal:
- Rakesh C Patel
-
Contact:
- Roshini Narayanaswamy
- E-mail: rnara@onsiteclinical.com
-
Wilmington, North Carolina, États-Unis, 28401
- Recrutement
- Carolina Arthritis Associates
-
Chercheur principal:
- Mark Harris
-
Contact:
- Jodi Daniel
- Numéro de téléphone: +1 910 762 1182
- E-mail: study@carolinaarthritis.com
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73116
- Recrutement
- RAO Research LLC
-
Contact:
- Mary Turner
- Numéro de téléphone: +1 405 608 8060
- E-mail: mturner@raoklahoma.com
-
Chercheur principal:
- John Goetzinger
-
-
Tennessee
-
Jackson, Tennessee, États-Unis, 38305
- Recrutement
- West Tennessee Research Institute
-
Chercheur principal:
- Jacob A Aelion
-
Contact:
- Judith Padilla
- Numéro de téléphone: +1 731 664 0002
- E-mail: jpadilla@arthritisclinic.org
-
Memphis, Tennessee, États-Unis, 38119
- Recrutement
- Shelby Research LLC
-
Chercheur principal:
- Ramesh C Gupta
-
Contact:
- Subhash Eedarapalli
- Numéro de téléphone: +1 901 681 9670
- E-mail: shelbyres261@outlook.com
-
-
Texas
-
Bellaire, Texas, États-Unis, 77401
- Recrutement
- Novel Research LLC
-
Chercheur principal:
- Wajeeha Yousaf
-
Contact:
- Hassan Khan
- Numéro de téléphone: +1 281 944 3610
- E-mail: khan@novelresearch.net
-
Corpus Christi, Texas, États-Unis, 78415
- Recrutement
- Arthritis Care of Texas
-
Contact:
- Tatum Trevino
- Numéro de téléphone: +1 361 400 7700
- E-mail: tatum.trevino@sclamanagement.com
-
Chercheur principal:
- Eric Ping Chiang
-
Euless, Texas, États-Unis, 76040
- Recrutement
- Precision Comprehensive Clinical Research Solutions
-
Chercheur principal:
- Renuka Basavaraju
-
Contact:
- Akshay Shetty
- E-mail: ashetty@pccrsolutions.com
-
Houston, Texas, États-Unis, 77024
- Recrutement
- Abigail Neiman MD PA
-
Chercheur principal:
- Abigail Neiman
-
Contact:
- Hina Arshad
- Numéro de téléphone: +1 832 834 5627
- E-mail: hina@novelresearch.net
-
League City, Texas, États-Unis, 77573
- Recrutement
- Accurate Clinical Research
-
Chercheur principal:
- Sabeen Najam
-
Contact:
- David Batista
- Numéro de téléphone: +1 281 422 7179
- E-mail: dbatista@accurateclinicalresearch.com
-
Leander, Texas, États-Unis, 78641
- Recrutement
- TEKTON
-
Chercheur principal:
- Paul K Pickrell
-
Contact:
- Stephanie Garcia
- Numéro de téléphone: +1 512 388 5717
- E-mail: sgarcia@tektonresearch.com
-
-
Washington
-
Spokane, Washington, États-Unis, 99216
- Recrutement
- Arthritis Northwest PLLC
-
Chercheur principal:
- Michael C Coan
-
Contact:
- Corine Nguyen
- Numéro de téléphone: +1 509 838 6500
- E-mail: cnguyen@arthritisnw.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Male or female participants ≥ 18 years of age or as per country-specific legal adult age, whichever is higher
- Classification of Sjögren's disease according to ACR/EULAR 2016 criteria.
- Seropositive for anti-Ro/SSA antibodies at screening
- SSSD oral dryness score ≥ 5 and overall SSSD summary score ≥5 collected over 14 consecutive days during the Screening 2 period
- Screening ESSDAI biologic and/or hematologic domain > 0 Note: laboratory abnormalities for scoring must be confirmed as associated with Sjögren's disease and not be due to other underlying conditions.
- Stimulated whole salivary flow (sSF) rate > 0.3 mL/min at screening
- Participants taking hydroxychloroquine (≤ 400 mg/day) are allowed to continue their medication, and must have been on a stable dose for at least 4 weeks prior to screening, which should be maintained throughout the 52 weeks of the blinded treatment period.
- Predniso(lo)ne ≤ 5 mg/day or equivalent are allowed for up to 16 weeks post-randomization.
Exclusion Criteria:
- Presence of another autoimmune rheumatic disease that is active and constitutes the principal illness, specifically:
- Systemic sclerosis (SSc)
- Any other associated connective tissue disease (e.g., lupus nephritis (LN), large vessel vasculitis (LVV), Sharp syndrome (mixed connective tissue disease)) that is active and requires immunosuppressive treatment outside the scope of this trial and would impede on Sjögren's disease organ domain assessments.
- Concurrent diagnosis or history of fibromyalgia or overlapping inflammatory diseases
- Prior treatment with B-cell-depleting therapy (e.g., rituximab, other anti-CD20 mAb, anti-CD22 mAb, or anti-CD52 mAb) within:
- 36 weeks prior to randomization, or
- As long as B-cell count is less than the lower limit of normal (LLN) or baseline value prior to receipt of previous B-cell-depleting therapy (whichever is lower) at Screening.
- Prior treatment with ianalumab
- Prior treatment with any of the following within the given period prior to Screening:
- Within 5 half-lives prior to Screening: iscalimab (anti-CD 40 mAb), belimumab (anti-BAFF mAb), abatacept (CTLA4-Fc Ig), anti-tumor necrosis factor alpha (TNFα) biologic agents, immunoglobulins (i.v./s.c.), plasmapheresis, any other investigational biologic medicines under investigation for Sjögren's disease
- Within 4 weeks OR drug-specific 5 half-lives elimination period (if longer than 4 weeks) prior to screening: i.v. or oral cyclophosphamide, mycophenolate mofetil (MMF), methotrexate, azathioprine, i.v. or oral cyclosporine A or any other immunosuppressants (e.g., JAK inhibitors or other kinase inhibitors).
- History of hypersensitivity to any of the study drugs or their excipients, or to drugs of similar chemical classes (e.g., mAb of IgG1 class) or to any of the constituents of the study drug formulation (sucrose, L-histidine hydrochloride/L-histidine, polysorbate 20).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: VAY736 - 300 mg
VAY736 once monthly solution for injection for subcutaneous use. |
VAY736 once monthly solution for injection for subcutaneous use.
Autres noms:
|
|
Comparateur placebo: Placebo
Placebo once monthly solution for injection for subcutaneous use. |
Placebo once monthly solution for injection for subcutaneous use. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change from baseline in SSSD oral dryness score
Délai: Baseline to Week 52
|
The Sjögren's Syndrome Symptom Diary (SSSD) oral dryness score is a patient-reported measure assessing severity of mouth dryness. The mouth dryness symptom is scored daily on a numerical scale (higher scores = worse symptoms). |
Baseline to Week 52
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change from baseline in SSSD summary score
Délai: Baseline to Week 52
|
The SSSD summary score is calculated over a defined time window. Each symptom is scored daily on a numerical scale (higher scores = worse symptoms). |
Baseline to Week 52
|
|
Change from baseline in ESSPRI score
Délai: Baseline to Week 52
|
The EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) score is a validated patient-reported outcome assessing three symptom domains: dryness, pain and fatigue. Scores range from 0 (no symptoms) to 10 (worst imaginable symptoms). |
Baseline to Week 52
|
|
Change from baseline in stimulated whole salivary flow (sSF)
Délai: Baseline to Week 52
|
The stimulated whole salivary flow rate, is an objective functional assessment of salivary gland activity, measuring saliva production under stimulation. Higher values indicate better salivary gland function. |
Baseline to Week 52
|
|
Change from baseline in Patient's Global Assessment (PaGA) NRS score
Délai: Baseline to Week 52
|
The Patient's Global Assessment of disease activity captures the patient's overall perception of disease activity. It is assessed using a Numerical Rating Scale (NRS) from 0 to 10. Higher scores indicate worse perceived disease activity. |
Baseline to Week 52
|
|
Proportion of participants achieving SSSD response
Délai: Week 52
|
Proportion of participants achieving a clinically meaningful improvement in the SSSD summary score at Week 52. |
Week 52
|
|
Proportion of participants achieving ESSPRI response
Délai: Week 52
|
Proportion of participants achieving a clinically meaningful improvement in the ESSPRI score at Week 52. |
Week 52
|
|
Change from baseline in SSSD eye dryness score
Délai: Baseline to Week 52
|
The SSSD eye dryness item score is a patient-reported measure assessing severity of eye dryness. The eye dryness symptom is scored daily on a numerical scale (higher scores = worse symptoms). |
Baseline to Week 52
|
|
Change from baseline in FACIT-Fatigue score
Délai: Baseline to Week 52
|
The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) score is a 13-item questionnaire assessing fatigue and its impact on daily activities over the previous 7 days. Higher scores indicate less fatigue / better functioning. |
Baseline to Week 52
|
|
Change from baseline in Sjögren's-Related Quality of Life (SRQoL) score
Délai: Baseline to Week 52
|
The Sjögren's-Related Quality of Life (SRQoL) score is a disease-specific quality-of-life instrument evaluating the impact of Sjögren's disease on physical, emotional, social and daily functioning. Lower scores indicate better quality of life. |
Baseline to Week 52
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies musculo-squelettiques
- Maladies de la bouche
- Maladies stomatognathiques
- Arthrite
- Maladies articulaires
- Maladies rhumatismales
- Maladies du tissu conjonctif
- Maladies du système immunitaire
- Maladies oculaires
- Arthrite, rhumatoïde
- Xérostomie
- Maladies des glandes salivaires
- Syndromes de sécheresse oculaire
- Maladies de l'appareil lacrymal
- Conditions pathologiques, signes et symptômes
- Maladies de la peau et du tissu conjonctif
- Signes et symptômes
- Fatigue
- Le syndrome de Sjogren
- Maladies auto-immunes
- ianalumab
Autres numéros d'identification d'étude
- CVAY736A22301
- 2025-522271-29-00 (Autre identifiant: EU CTR)
- 2025 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .